Transgene Biotek

Which are the latest news on Transgene Biotek?

Why is Transgene Biotek Ltd falling/rising?

As of 05-Sep, Transgene Biotek Ltd's stock price is at 2.72, reflecting a decline of 1.81%. The stock has underperformed significantly over various time frames, trading below key moving averages and experiencing low liquidity despite increased investor participation.

As of 05-Sep, Transgene Biotek Ltd's stock price is falling, currently at 2.72, which reflects a decrease of 0.05 or 1.81%. This decline is part of a broader trend, as the stock has underperformed significantly over various time frames, including a 1-week drop of 6.21% and a 1-month decrease of 13.10%. Year-to-date, the stock has fallen by 13.65%, and over the past year, it has decreased by 32.17%. <BR><BR>Despite today's performance indicating that the stock outperformed its sector by 0.54%, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Additionally, while there has been a notable increase in investor participation, with delivery volume rising by 89.02% against the 5-day average, the overall liquidity remains low, suggesting that trading activity is not sufficient to counteract the downward price movement. Overall, these factors contribute to the stock's current decline.

Who are in the management team of Transgene Biotek?

The management team of Transgene Biotek includes K Koteswara Rao (Chairman & Managing Director), Ankita Jain (Company Secretary & Compliance Officer), and independent directors Sujana Kadiam, Santosh Kumar, and Marri Swetha.

The management team of Transgene Biotek includes the following members:<BR><BR>1. **K Koteswara Rao** - Chairman & Managing Director<BR>2. **Ankita Jain** - Company Secretary & Compliance Officer<BR>3. **Sujana Kadiam** - Independent Director<BR>4. **Santosh Kumar** - Independent Director<BR>5. **Marri Swetha** - Independent Director<BR><BR>If you need more specific information about their roles or backgrounds, feel free to ask!

What does Transgene Biotek do?

Transgene Biotek Ltd is a biotechnology company focused on developing diagnostic kits, vaccines, and drug delivery technologies, with a market cap of INR 22 Cr. As of June 2026, it reported net sales and net profit of 0 Cr.

Overview: <BR>Transgene Biotek Ltd is a biotechnology company engaged in research and development in the healthcare services industry, specifically focusing on diagnostic kits, vaccines, oncology, and new drug delivery technologies. It falls under the micro-cap market category.<BR><BR>History: <BR>Transgene Biotek Ltd was founded in March 1990 by Dr. Koteswara Rao. The company initially manufactured and sold diagnostic kits before transitioning to biotech research. The most recent quarterly results reported net sales and net profit of 0 Cr for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 22 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 2.04 <BR>Return on Equity: -19.69% <BR>Price to Book: 2.62<BR><BR>Contact Details: <BR>Address: Plot No 69 & 70 IDA Bollaram, Sangareddy Telangana: 502325 <BR>Website: http://www.transgenebiotek.com

Who are the peers of the Transgene Biotek?

Transgene Biotek's peers include Chennai Meena, Tejnaksh Health, Samsrita Labs, Adeshwar Meditex, Vanta Bioscience, Family Care, Dhanvantri Jeev, Looks Health, and Clinitech Lab. Notably, Dhanvantri Jeev has the highest 1-year return at 26.19%, while Transgene Biotek's return is -27.06%.

Peers: The peers of Transgene Biotek are Chennai Meena, Tejnaksh Health., Samsrita Labs, Adeshwar Meditex, Vanta Bioscience, Family Care, Dhanvantri Jeev., Looks Health, Clinitech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Average management risk is found at Adeshwar Meditex and Vanta Bioscience, and the rest have Below Average or do not qualify. Good growth is noted at Family Care, while Below Average growth is present at Tejnaksh Health., Adeshwar Meditex, Vanta Bioscience, Dhanvantri Jeev., and Clinitech Lab, and the rest do not qualify. Average capital structure is seen at Adeshwar Meditex, Good at Tejnaksh Health. and Dhanvantri Jeev., and Excellent at Family Care, while Below Average is noted at Vanta Bioscience and Clinitech Lab, and the rest do not qualify.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Tejnaksh Health. has the lowest at -25.80%, and Transgene Biotek's own 1-year return is -27.06%. Additionally, several peers, including Samsrita Labs, Family Care, and Clinitech Lab, have negative six-month returns.

How big is Transgene Biotek?

As of 31st August, Transgene Biotek Ltd has a market capitalization of 22.00 Cr and reported net sales of 0.21 Cr with a loss of 1.61 Cr over the latest four quarters. Shareholder's funds are 10.03 Cr, and total assets amount to 144.09 Cr.

As of 31st August, Transgene Biotek Ltd has a market capitalization of 22.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Transgene Biotek reported net sales of 0.21 Cr. However, the company experienced a loss of 1.61 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's funds are recorded at 10.03 Cr, while total assets amount to 144.09 Cr.

When is the next results date for Transgene Biotek Ltd?

The next results date for Transgene Biotek Ltd is 07 August 2026.

The next results date for Transgene Biotek Ltd is scheduled for 07 August 2026.

How has been the historical performance of Transgene Biotek?

Transgene Biotek has seen a rise in net sales from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, but continues to report negative operating profits, with a loss of -1.13 Cr in Mar'25 and increasing total expenditures of 1.39 Cr. The company faces ongoing financial challenges, reflected in persistent losses before and after tax, and stagnant cash flow from operations.

Answer:<BR>The historical performance of Transgene Biotek shows a gradual increase in net sales, rising from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25. However, the company has consistently reported negative operating profits, with an operating profit of -1.13 Cr in Mar'25, indicating a worsening trend compared to -0.62 Cr in Mar'24. The total expenditure has also increased significantly, reaching 1.39 Cr in Mar'25 from 0.85 Cr in Mar'24. The profit before tax has remained negative, with a loss of -0.68 Cr in Mar'25, slightly worse than -0.66 Cr in Mar'24. The net profit after tax also reflects this trend, showing a loss of -0.68 Cr in Mar'25 compared to -0.66 Cr in Mar'24. The company's total liabilities have remained relatively stable at 142.33 Cr in Mar'24, down from 142.36 Cr in Mar'23. The cash flow from operating activities has been stagnant, with no cash inflow reported in recent years.<BR><BR>Breakdown:<BR>Transgene Biotek's financial performance reveals a mixed picture over the years. Net sales have shown a positive trend, increasing from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, yet the company continues to face significant challenges with operating profits, which have remained negative, culminating in -1.13 Cr in Mar'25. The total expenditure has escalated to 1.39 Cr, contributing to a profit before tax of -0.68 Cr in Mar'25, indicating persistent financial strain. The net profit after tax mirrors this situation, with a loss of -0.68 Cr. Despite a stable total liability figure of 142.33 Cr in Mar'24, the company's cash flow from operations has not improved, reflecting ongoing operational difficulties. Overall, while there is a slight increase in sales, the underlying profitability issues and rising expenditures suggest that Transgene Biotek is still navigating a challenging financial landscape.

Who are the top shareholders of the Transgene Biotek?

The top shareholder of Transgene Biotek is Dr. K Koteswara Rao, holding 21.89% of shares, while individual investors collectively own 71.88%. There are no institutional shareholders, mutual fund schemes, or pledged promoter holdings.

The top shareholders of Transgene Biotek include Dr. K Koteswara Rao, who holds the largest share at 21.89%. The majority of the company's shares are held by individual investors, accounting for 71.88% of the total holdings. There are no institutional shareholders or mutual fund schemes involved, and there are no pledged promoter holdings. The highest public shareholder is categorized as "Other Shr Off Family," but they hold 0%. Overall, the shareholding structure indicates a strong presence of individual investors in the company.

Is Transgene Biotek overvalued or undervalued?

As of April 25, 2023, Transgene Biotek is considered risky and overvalued, with a PE ratio of -30.23 and a year-to-date return of -42.61%, significantly underperforming compared to peers and the Sensex.

As of 25 April 2023, the valuation grade for Transgene Biotek has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -30.23, an EV to EBITDA of -39.71, and a Price to Book Value of 3.01. In comparison to peers, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals stands at 69.03, indicating that Transgene Biotek's valuation metrics are significantly weaker.<BR><BR>The company's recent performance has also been disappointing, with a year-to-date return of -42.61%, contrasting sharply with the Sensex's gain of 5.58% over the same period. This underperformance, coupled with negative returns over various time frames, reinforces the conclusion that Transgene Biotek is overvalued in the current market environment.

What is the technical trend for Transgene Biotek?

As of May 14, 2025, Transgene Biotek's technical trend is mildly bearish, with mixed signals across various indicators showing a shift from bearish to mildly bullish on the weekly timeframe, while remaining bearish on the monthly.

As of 14 May 2025, the technical trend for Transgene Biotek has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are showing a mildly bearish trend, and the Bollinger Bands are sideways on the weekly chart but bearish on the monthly. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory shows a mildly bullish trend on the weekly timeframe with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven by the mixed signals across different time frames and indicators.

Has Transgene Biotek declared dividend?

No Dividend History Available